



Store-Operated Calcium Channels Contribute to Remifentanyl-Induced Postoperative Hyperalgesia via Phosphorylation of CaMKII α in Rats

Zhenhui Zhou ^{1,*}Meng Mao ^{2,*}Xuechun Cai ¹Wei Zhu ¹Jie Sun ³

¹Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China; ²Department of Anesthesiology, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China; ³Department of Anesthesiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China

*These authors contributed equally to this work

Correspondence: Jie Sun
Department of Anesthesiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, People's Republic of China
Tel +8615895971012
Email dgsunjie@hotmail.com

Wei Zhu
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, People's Republic of China
Tel +8618905182820
Email zhuweijsp@163.com

Purpose: The mechanisms of remifentanyl-induced postoperative hyperalgesia (RIPH) remain unclear. Store-operated calcium channels (SOCCs) are mainly comprised of stromal interaction molecules 1 (STIM1) and pore-forming subunits (Orai1). They were found to take a pivotal part in Ca²⁺-dependent procedures and involved in the development of central sensitization and pain. Ca²⁺/calmodulin-dependent protein kinase II α (CaMKII α), regulated by Ca²⁺/calmodulin complex, has been shown to have a crucial role in RIPH. This study aims to determine whether SOCCs contribute to RIPH via activating CaMKII α .

Materials and Methods: Intra-operative infusion of remifentanyl (1.0 $\mu\text{g kg}^{-1} \text{min}^{-1}$, 60 min) was used to establish a RIPH rat model. The SOCCs blocker (YM-58483) was applied intrathecally to confirm the results. Animal behavioral tests including paw withdrawal thermal latency (PWTl) and paw withdrawal mechanical threshold (PWMT) were performed at -24, 2, 6, 24, 48 h after incision and remifentanyl treatments. The protein expression of STIM1, Orai1, CaMKII α , and p-CaMKII α was assayed with Western blot, and the number of STIM1 and Orai1 positive cells was shown by immunofluorescence.

Results: Remifentanyl administration significantly induced postoperative mechanical and thermal hyperalgesia, as well as increased STIM1 and Orai1 protein expression in the spinal dorsal horn. Furthermore, the intrathecal administration of YM-58483 effectively alleviated remifentanyl-induced postoperative mechanical and thermal hyperalgesia according to the behavioral tests. In addition, YM-58483 suppressed the phosphorylation of CaMKII α but had no effect on the expression of STIM1 and Orai1.

Conclusion: Our study demonstrated that SOCCs are involved in RIPH. The over-expressed STIM1 and Orai1 in the spinal cord contribute to RIPH via mediating the phosphorylation of CaMKII α . Blockade of SOCCs may provide an effective therapeutic approach for RIPH.

Keywords: remifentanyl, hyperalgesia, SOCCs, CaMKII α

Introduction

Remifentanyl is a potent short-acting μ -opioid receptor agonist that has unique pharmacokinetic properties with rapid metabolism, making it a common intraoperative analgesic.¹ Although it is widely used in the clinic, increasing experimental and clinical researches suggested that remifentanyl is associated with paradoxical nociceptive effect, known as remifentanyl-induced postoperative hyperalgesia (RIPH).²⁻⁵ There have been studies investigating how remifentanyl causes hyperalgesia; however, the specific mechanism remains unclear.

Store-operated calcium channels (SOCCs) are Ca^{2+} -selective cation channels, which are implicated in the Ca^{2+} influx pathway in many different cell types. The SOCCs system is comprised of stromal interaction molecules (STIM) and pore-forming subunits (Orai). The STIM is located on the surface of the endoplasmic reticulum (ER), and the Orai is located in the plasma membrane.⁶ Especially, STIM1 and Orai1, two key components of SOCCs, play a crucial role in mediating store-operated Ca^{2+} entry (SOCE) and maintaining resting calcium homeostasis.⁷ In neurons, Ca^{2+} is crucial to the development of long-term potentiation (LTP) in the synaptic plasticity, which leads to the formation and the maintenance of pain hypersensitivity.⁸ Accumulated evidence has been manifested that all the components of SOCCs are expressed in the central nervous system (CNS) and involved in neuronal functions and pathological status, such as Parkinson's disease (PD),⁹ Alzheimer's disease (AD),¹⁰ and chronic pain.^{11,12} In addition, SOCE is activated by the depletion of ER calcium stores and can be blocked by YM-58483, a potent SOCCs channel blocker.¹¹ Recent studies reported that YM-58483 was able to reverse thermal and mechanical hypersensitivity in spared nerve injury (SNI) and inflammatory pain models.^{13,14} However, the relationship between SOCCs and RIPH remains to be elusive.

Ca^{2+} /calmodulin-dependent protein kinase II α (CaMKII α), a multifunctional serine/threonine kinase, was gradually revealed a vital role in forming and maintaining RIPH.^{15,16} CaMKII α is regulated by Ca^{2+} /calmodulin complex. Elevated intracellular Ca^{2+} and calmodulin levels are essential in the activation of CaMKII α .¹⁷ CaMKII α is involved in LTP and synaptic plasticity by decoding synaptic Ca^{2+} oscillations.^{18,19} Temporarily elevated levels of p-CaMKII α in the CNS are associated with central sensitization and pain hypersensitivity.²⁰ Furthermore, SOCE induced by chronic ER Ca^{2+} depletion may lead to increased intracytoplasmic Ca^{2+} concentration, resulting in CaMKII α activation.²¹ Therefore, we hypothesized that the inhibition of SOCE could reduce the phosphorylation of CaMKII α in the spinal cord, thereby alleviating RIPH.

In the present study, we investigated the expression level of SOCCs in the spinal dorsal horn by establishing a rat model of RIPH. Since CaMKII α is activated by Ca^{2+} and involved in RIPH, we next explored whether SOCCs contribute to RIPH via phosphorylation of CaMKII α . Our

results provide a molecular mechanism and therapeutic approach on RIPH.

Materials and Methods

Animals

Mature male Sprague Dawley rats (2–3 months old, 360–380 g) were purchased from the Zhejiang Academy of Medical Sciences. All procedures were performed following the approved guidelines of Southeast University, and all animal model experiments were tested with the approval of the Animal Experimental Ethics Committee of Southeast University (Ethical permission code: 20200310006). Rats were housed under controlled environmental conditions (room temperature of 24 ± 1 °C and relative humidity of $55\% \pm 10\%$) with a 12-h light/dark cycle. Five rats per cage were received standard rats chow and water ad libitum. The rats were randomly divided into four groups in each experiment, with 10 rats in each group before any assessment was performed.

Surgical Procedure

The plantar incision was performed as described in the previous article.²² A 1.0 cm longitudinal plantar incision through the skin and fascia of the right hind paw from the edge of the heel to the toe was made with a No. 11 blade. The plantaris muscle was separated by ophthalmic forceps and incised longitudinally, and the tendon should be protected from being severed. The skin was sutured with 4–0 sutures, and the wound site was covered with Aureomycin ointment to prevent infection. Rats in the control group received sham procedures without skin incisions.

Experiment Related Procedures

For intravenous drug administration, a 24-gauge catheter rinsed with heparinized saline (100U/mL) was cannulated in the rat tail vein. For intrathecal drug administration, a lumbar puncture technique was used to accomplish a successful intrathecal injection.²³ Sevoflurane anesthetized rats were placed in the prone position, exposing the lumbar vertebral space between L4 and L5. A 20 μL microinjector was inserted vertically into the lumbar intervertebral space. Brisk tail movement indicated successful intrathecal injection.

Drug Administration

Remifentanyl (Yichang Renfu Pharmaceutical Co., Yichang, China) was dissolved in 0.9% saline and injected intravenously (i.v.) for 60 minutes, the infusion rate was 1.0

$\mu\text{g}^{-1}\cdot\text{kg}^{-1}\cdot\text{min}$. Rats in the control group received the same volume of saline ($0.1\text{ mL kg}^{-1}\text{ min}^{-1}$, 60 min). YM-58483 (MedChemexpress LLC, Princeton, NJ, USA) was dissolved in PEG300 (MedChemexpress LLC, Princeton, NJ, USA) and injected intrathecally (i.th.) at the concentration of $10\ \mu\text{L}$ ($1000\ \mu\text{mol/L}$) 2 h before each behavior test. The same volume of PEG300 was used as the control treatment. All drugs were administered under sevoflurane anesthesia (induction, 3.0%; maintenance, 1.0%; Hengrui Pharmaceutical Co., Ltd, Shanghai, China). The detailed process and grouping of the experiment are shown in Figure 1A–D.

Nociceptive Behavioral Tests

Paw withdrawal mechanical threshold (PWMT) was measured using von Frey filaments (Aesthesio, Danmic Global, LLC, Campbell, CA, USA) according to the “up-down” method.²⁴ Briefly, each rat was placed in an individual plastic box with a metallic mesh bottom and acclimated for 30 min. The calibrated filaments were perpendicular to the plantar surface of the hind paw for 6 s, and the positive response was defined as a brisk paw withdrawal or flinching. Under the condition of a positive response, the next lower force filament was applied. If in a negative response, the next greater force filament was applied. The up-down algorithm was applied to calculate the 50% likelihood of the PWMT.²⁵

Paw withdrawal thermal latency (PWTL) was measured using a thermal testing apparatus (BME-410C, Inst of Biomedical Engineering, CAMS, Tianjin, China). Each rat was placed in an individual plastic box on a glass surface and acclimated for 30 min. The targeted hind paw was focused by a mobile radiant heat source located under the glass until the positive response occurred, and the time was recorded as the PWTL. The test was repeated three times at 10-min intervals. The average value of the three trials was evaluated as the mean PWTL. To protect from potential tissue damage, a 30 s cut-off was set.²⁵ The observer of behavioral tests was blinded to the treatment.

PWMT and PWTL were measured at 24 hours before remifentanil administration as baseline and then at 2, 6, 24, and 48 hours after remifentanil administration.

Western Blot


After the last behavioral test at 48 h, rats were deeply anesthetized with sevoflurane and spinal cord tissues were removed from the enlarged lumbar region (L4–L6) for Western blotting analysis. Spinal cord tissues were extracted in RIPA buffer (Beyotime Biotech Inc., Shanghai, China) containing protease and phosphatase inhibitors. After

centrifuging ($\times 12,000\text{ rpm}$) at 4°C for 20 min, the supernatant fluid of each sample was obtained and protein concentration was detected by BCA protein assay. Twenty-four micrograms of each protein sample was electrophoresis with 10% SDS-PAGE, then transferred to PVDF membrane (Millipore Corp, Billerica, MA, USA). The membrane was blocked with 5% bovine serum albumin for 1 h at room temperature and then incubated with the following primary antibodies: rabbit monoclonal anti-STIM1 (#5668, 1:1000, CST, Danvers, MA, USA), mouse monoclonal anti-Orail (ab175040, $5\ \mu\text{g}/\mu\text{L}$, Abcam, Cambridge, UK), rabbit monoclonal anti-phospho-CaMKII (Thr286) (#12716, 1:1000, CST, Danvers, MA, USA), mouse monoclonal anti-CaMKII α (6G9) (#50049, 1:1000, CST, Danvers, MA, USA) and rabbit anti-GADPH (#10494-1-AP, 1:20000, Proteintech, Wuhan, China) overnight at 4°C . The biotinylated secondary antibody (anti-rabbit IgG (GB23303, 1:3000, Servicebio Technology Co., Ltd, Wuhan, China) or anti-mouse IgG (GB23301, 1:3000, Servicebio Technology Co., Ltd, Wuhan, China)) was used to incubate the membranes for 1 h at room temperature. After rinsing in TBST and incubated in ECL liquid ((Beyotime Biotech Inc., Shanghai, China), target protein bands were detected using a ChemiScope6100 imaging system (Clinx Science Instruments, Co., Ltd, Shanghai, China) and quantified by the Image J software (National Institute of Health, Bethesda, MD, USA).

Immunofluorescence

After the last behavioral test at 48 h, rats were deeply anesthetized with sevoflurane and instilled with 0.1 M phosphate buffer saline (PBS) and 4% paraformaldehyde (PFA). The L4–L6 spinal cords were rapidly removed, post-fixed in 4% PFA for 24 h and dehydrated in 30% sucrose at 4°C for 72 h. Spinal cord tissues were embedded with O.C.T. Compound (SAKURA Tissue-Tek[®] O.C.T. Compound, Sakura Finetek, USA) and cut into $30\text{-}\mu\text{m}$ -thick sections using a freezing microtome. Tissue sections were permeabilized in PBS containing 0.1% Triton X-100 for 2 h after being rinsed in PBS and then blocked in 10% bovine serum albumin for 1 h. Sections were then incubated with the mixed primary antibodies (rabbit anti-STIM1, #5668, 1:200, CST, Danvers, MA, USA, Orail; mouse anti-Orail ab175040, $1\ \mu\text{g}/\mu\text{L}$, Abcam, Cambridge, UK) for 48 h at 4°C . Subsequently, sections were washed in PBS and incubated with the blended secondary antibodies (Alexa Fluor 488 conjugated to goat anti-mouse IgG, 1:500, Proteintech, Wuhan, China; Alexa Fluor 532 conjugated to goat anti-rabbit IgG, $5\ \mu\text{g}/\text{mL}$, Invitrogen,


Experiment 1



B

Groups(n=10)	Treatments
NS	Saline $0.1 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , i.v.), without incision
Inci	Saline $0.1 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , i.v.)+incision
Remi	Remifentanil $1.0 \mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , i.v.), without incision
Inci+Remi	Remifentanil $1.0 \mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , iv.)+incision

Experiment 2



D

Groups(n=10)	Treatments
NS+Vehicle	Saline $0.1 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , i.v.), without incision+PEG300 $10 \mu\text{l}$, i.th.
Inci+Vehicle	Saline $0.1 \text{ ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , i.v.)+incision+PEG300 $10 \mu\text{l}$, i.th.
Inci+Remi+Vehicle	Remifentanil $1.0 \mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , iv.)+incision+PEG300 $10 \mu\text{l}$, i.th.
Inci+Remi+YM-58483	Remifentanil $1.0 \mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (60min , iv.)+incision+YM-58483 10nmol , i.th.

Figure 1 Detailed process and grouping of the experiment.

Notes: (A and B) Experiment 1 is to establish a rat RIPH model and investigate whether SOCCs are involved in RIPH. (C and D) Experiment 2 is to examine the effect of YM-58483 on RIPH and further confirm the mechanism of SOCCs involvement in RIPH.

Abbreviations: RIPH, remifentanil-induced postoperative hyperalgesia; SOCCs, store-operated calcium channels.

Carlsbad, CA, USA) for 24 h. Images were acquired with a fluorescence microscope (MF31, Mshot, Guangzhou, China). Every slide was captured three selected fields under $10\times$ magnification and counted the number of positive cells.

Statistical Analysis

Data were shown as means \pm SEM. Two-way analysis of variance (ANOVA) followed by Dunnett's post hoc test was applied to analyze the behavioral data. One-way ANOVA followed by Tukey's post hoc test was applied to analyze the

Western blot and immunohistochemistry data. All statistical analyses were performed using GraphPad Prism version 8.3 (GraphPad Software Inc., San Diego, CA, USA). $P < 0.05$ was considered to be statistically significant.

Result

Remifentanil-Induced Mechanical and Thermal Hyperalgesia in Rats

As shown in Figure 2A and B, there were no significant differences in basic values of PWMT and PWTL among all groups ($P > 0.05$). Compared with baseline, PWMT and PWTL decreased in Inci, Remi and Inci + Remi groups ($P < 0.05$) at different time points, and they did not show significant changes in NS group ($P > 0.05$). Compared with NS group, PWMT decreased from 2 to 24 h and PWTL decreased from 2 to 48 h in Remi group ($P < 0.05$). Furthermore, compared with Inci group, PWMT decreased from 6 to 48 h and PWTL decreased from 2 to 48 h in Inci + Remi group ($P < 0.05$). These results indicated that the RIPH model was successfully established.

The Expression of STIM1 and Orai1 in the Spinal Dorsal Horn Increased After Remifentanil Administration

To determine the effect of remifentanil on STIM1 and Orai1 expression in the spinal cord, we detected the SOCCs expression at 48 h after the administration of remifentanil. The Western blot analysis of homogenized spinal tissues showed STIM1 and Orai1 levels were significantly increased in Inci (STIM1: $P < 0.05$; Orai1: $P < 0.01$), Remi (STIM1: $P < 0.01$; Orai1: $P < 0.001$), and Inci + Remi (STIM1:

$P < 0.001$; Orai1: $P < 0.001$) groups as compared with NS group (Figure 3A–C). Compared with Inci group, the expression of STIM1 and Orai1 were increased in Inci + Remi group (STIM1: $P < 0.001$; Orai1: $P < 0.001$) (Figure 3A–C).

Since previous studies showed that STIM1 and Orai1 are mainly expressed in the spinal dorsal horn neurons, and the decreased concentration of ER Ca^{2+} stores increases STIM1 and Orai1 puncta formation in vitro.^{11,12} Thus, we detected the number of STIM1 and Orai1 in the spinal dorsal horn. As shown in Figure 3D–F, STIM1 and Orai1 collocated in the same spinal cord cells. Consistent with the Western blot results above, remifentanil administration significantly increased the number of STIM1 and Orai1 positive cells ($P < 0.001$).

Blocking of SOCCs Reversed RIPH

To further verify the effect of SOCCs on RIPH, a specific blocker of the SOCCs, YM-58483 was intrathecally injected into rats 2 h before each behavior testing. As shown in Figure 4A and B, compared with Inci + Remi + Vehicle group, administration of YM-58483 (10 nmol) with incision and remifentanil significantly increased PWMT and PWTL ($P < 0.05$). Interestingly, we did not detect a difference between Inci + Vehicle group and Inci + Remi + YM-58483 group ($P > 0.05$).

YM-58483 Decreased Remifentanil-Induced Phosphorylation of CaMKII α in the Spinal Cord

Next, Western blot data demonstrated that intrathecal treatment with SOCCs blocker, YM-58483, did not affect the




Figure 2 The effect of RIPH.

Notes: The basic values of PWMT (A) and PWTL (B) were similar in all groups. Both incision and remifentanil significantly decreased PWMT (A) and PWTL (B) compared with group NS. Furthermore, remifentanil infusion significantly increased incision-induced thermal and mechanical hyperalgesia. All the data are expressed as means \pm SEM ($n = 10$) and analyzed by two-way ANOVA with Dunnett post hoc comparisons. * $P < 0.05$ vs baseline; # $P < 0.05$ vs group NS; & $P < 0.05$ vs group Inci.

Abbreviations: PWTL, paw withdrawal thermal latency; PWMT, paw withdrawal mechanical threshold; SEM, standard error of measurement; ANOVA, analysis of variance; h, hours.




Figure 3 Expression of STIM1 and Orail in rat spinal dorsal horn after RIPH.

Notes: Representative blot images (A) and statistical analysis of STIM1 and Orail protein expression (B and C) in the spinal cord (n=4). The amount of STIM1 and Orail proteins (85 and 48 kDa) was normalized to that of GAPDH (36 kDa) in the same sample, and the mean STIM1 and Orail level in control rats were considered to be 1. Representative double immunofluorescence labeling images (D) and statistical analysis of positive cells (F) of STIM1 and Orail in the spinal dorsal horn (E). Three selected fields in 3 serial sections were analyzed under a fluorescence microscope (×10; n=3). Scale bar: both 1 and 2 are 100 μm. Data are expressed as means ± SEM and analyzed by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. **Abbreviations:** STIM1, stromal interaction molecules 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.




Figure 4 The effect of YM-58483 on RIPH.

Notes: Intrathecal injection of YM-58483 attenuated remifentanyl-induced postoperative mechanical (A) and thermal (B) hyperalgesia. There was no difference between group Inci + Vehicle and group Inci + Remi + Vehicle. All the data are expressed as means \pm SEM ($n = 10$) and analyzed by two-way ANOVA with Dunnett post hoc comparisons. * $P < 0.05$ vs baseline; # $P < 0.05$ vs group NS + Vehicle; & $P < 0.05$ vs group Inci + Vehicle; @ $P < 0.05$ vs group Inci + Remi + Vehicle.

Abbreviation: h, hours.

expression of STIM1 and Orail in RIPH ($P > 0.05$) (Figure 5A–C). Studies have manifested that the phosphorylation of CaMKII α plays a crucial role in RIPH.²⁰ Thus, we further determined whether the phosphorylation of CaMKII α were involved in RIPH via increased Ca²⁺ induced by SOCE. Compared NS + vehicle group, the expression of p-CaMKII α was significantly increased in Inci + vehicle group ($P < 0.01$) and Inci + Remi + vehicle group ($P < 0.001$) (Figure 5D and E). Moreover, YM-58483 suppressed the level of p-CaMKII α compared with the Inci + Remi + vehicle group ($P < 0.01$) (Figure 5D and E). In addition, the protein level of CaMKII α did not demonstrate a significant difference among all groups ($P > 0.05$) (Figure 5D and F).

Discussion

Our results suggested that SOCCs play a crucial role in RIPH. The increase of the STIM1 and Orail protein was seen in remifentanyl used rats' spinal dorsal horn. Furthermore, remifentanyl infusion downregulated the nociceptive thresholds (PWMT and PWTL) at different time points, which could be partly improved by YM-58483, a potent SOCCs channel blocker. The expression of p-CaMKII α was partly reversed by YM-58483. It is indicated that blockade of SOCCs could regulate the expression of p-CaMKII α to prevent the RIPH.

Hyperalgesia refers to increased pain from a stimulus that usually provokes pain, including a reduced pain threshold and an increased response to subnormal stimuli.²⁶ Opioid-induced hyperalgesia (OIH) is known

as a paradoxical increase in sensitivity to painful stimuli associated with opioid therapy, resulting in slower patient's recovery after surgery and more consumption of analgesics.^{27,28} As a kind of opioid, remifentanyl is widely used in general anesthesia due to its unique properties. Indeed, remifentanyl has high lipid solubility, allowing for a rapid onset of effect; It is rapidly metabolized by non-specific plasma and tissue esterases and hence a rapid recovery.¹ Although remifentanyl offers significant advantages in the clinic, compared with other opioids, it has the highest reported incidence of hyperalgesia, known as remifentanyl-induced hyperalgesia (RIH).²⁹ With regard to the postoperative period, RIH results in increased opioid consumption and pain sensibility, which causes discomfort in patients and longer stay in hospital than expected.

Evidence from both human and animal models has reported that RIH is caused by exposure to a high dosage of remifentanyl.³⁰ Clinical trials are difficult to draw conclusions about the incidence of RIH due to heterogeneity of remifentanyl infusion regimens, maintenance of anesthesia, duration of infusion, cumulative dose of remifentanyl, and pain measures. However, it appears that intraoperative remifentanyl infusion rates greater than $0.2 \mu\text{g}^{-1} \cdot \text{kg}^{-1} \cdot \text{min}$ is associated with lower pain thresholds, which suggests hyperalgesia.¹ On the other hand, animal researches showed that $1.0 \mu\text{g}^{-1} \cdot \text{kg}^{-1} \cdot \text{min}$ for 60 min could induce hyperalgesia in rats. Therefore, the dosage of remifentanyl ($1.0 \mu\text{g}^{-1} \cdot \text{kg}^{-1} \cdot \text{min}$, 60 min) was chosen to establish a rat model of hyperalgesia, which approximates the equivalent dose conversed between humans and rats.³¹ Furthermore,




Figure 5 The effects of YM-58483 on SOCCs and p-CaMKII α after RIPH.

Notes: Representative blot images (A) and statistical analysis of STIM1 and Orai1 protein expression (B and C) in the spinal cord (n=4). The amount of STIM1 and Orai1 proteins (85 and 48 kDa) was normalized to that of GAPDH (36 kDa) in the same sample, and the mean STIM1 and Orai1 level in control rats were considered to be 1. Representative blot images (D) and quantification (E and F) of p-CaMKII α and CaMKII α protein levels in the spinal cord (n=4). The amount of p-CaMKII α and CaMKII α proteins (52 kDa) was normalized to that of GAPDH (36 kDa) in the same sample, and the mean p-CaMKII α and CaMKII α level in control rats was considered to be 1. Data are expressed as means \pm SEM and analyzed by one-way ANOVA and person correlation analysis. *P < 0.05, **P < 0.01, ***P < 0.001.

Abbreviation: CaMKII α , Ca²⁺/calmodulin-dependent protein kinase II α .

remifentanyl anesthesia during operation is more common in clinical practice; thus, we investigated the effects of incision plus remifentanyl on pain sensitivity. Interestingly, intra-operative exposure to remifentanyl apparently increased the incision-induced mechanical and thermal hyperalgesia.

SOCCs are activated by the release or depletion of Ca²⁺ from the ER, influencing neurotransmitter release and synaptic plasticity.^{32,33} SOCE is a major mechanism for triggering Ca²⁺ enter into cells, which is required for many Ca²⁺-dependent cellular functions, such as enzymatic activity. There are two key components of SOCCs—stromal interaction molecule 1 (STIM1) and Orai1.³⁴ Growing evidence manifests that SOCCs play a crucial role in pain disorders, such as SNI, inflammation, and acute pain.^{13,35,36} Our results indicated that continuous

remifentanyl infusion increases the expression level of STIM1 and Orai1 in the spinal dorsal horn, which has a vital effect on maintained remifentanyl-induced thermal and mechanical hypersensitivities. Furthermore, YM-58483, a potent SOCCs channel blocker, was reported to have analgesic actions in both acute and chronic pain.¹³ Our behavior testing results confirmed that intrathecal administration of YM-58483 reversed thermal and mechanical hyperalgesia, suggesting an action of SOCCs in regulating RIPH.

However, we further tested the protein expression of STIM1 and Orai1 by Western blot and found that YM-58483 could not decrease their levels during the development of RIPH. It is well documented that a decrease in ER Ca²⁺ leads to the intracellular redistribution of STIM1 at the ER membrane. The STIM1 puncta activates the Orai1

channel at the plasma membrane, allowing Ca^{2+} entry into the cellular.¹² However, the core mechanisms of action remain to be determined. Previous studies have manifested that YM-58483 blocks SOCE and dose-dependently inhibits the CaMKII α activation in arthritic pain models.¹⁴ Our results showed that the analgesic effect of YM-58483 in RIPH is not through impacting the expression of SOCCs. Thus, we further detected the protein expression of CaMKII α and p-CaMKII α .

CaMKII α , as a major CaMKII isoform expressed in the CNS, is an essential cellular mechanism leading to and maintaining OIH.³⁷ CaMKII α is activated by increased intracellular Ca^{2+} . Phosphorylated CaMKII α is a part of LTP hypersensitivity signaling, which is involved in the sensitization of homosynapses leading to an enhanced strength of the synapse and its signal transduction. Indeed, cumulative studies confirmed that inhibiting the activation of CaMKII α attenuates RIPH.^{38,39} Furthermore, SOCCs have been shown implicated in CaMKII α activation and YM-58483 effectively inhibits the CaMKII α activation in the spinal cord in different pain models.^{14,40} Our results indicated that CaMKII α becomes activated after the

intra-operative infusion of remifentanyl and that this increased phosphorylation of CaMKII α was significantly suppressed by YM-58483.

Together, these results above indicated that exposure to remifentanyl up-regulates STIM1 and Orai1 protein expression, further enhancing the SOCE. Increased intracellular Ca^{2+} leads to the phosphorylation of CaMKII α , which is part of LTP hypersensitivity signaling contributing to RIPH (Figure 6).

Conclusion

In summary, our study demonstrated that SOCCs in rat spinal dorsal horn contribute to the development of RIPH via activation of CaMKII α . The pharmacologic intervention of SOCCs protected against the development of hyperalgesia. Thus, the identification of SOCCs opens the way for targeted treatment and the blockade of the SOCCs/p-CaMKII α pathway is a new therapeutic target. However, how SOCCs are activated after the administration of remifentanyl is unclear. Further studies on the upstream mechanisms of SOCCs are encouraged to examine the relationship with RIPH.




Figure 6 Probable signaling pathway for RIPH.

Notes: The protein expression of STIM1 and Orai1 are up-regulated after remifentanyl infusion, which further enhances the store-operated Ca^{2+} entry (SOCE). Increased intracellular Ca^{2+} leads to the phosphorylation of CaMKII α . Moreover, CaMKII α and its activation are parts of LTP hypersensitivity signaling which contributes to RIPH.
Abbreviations: SOCE, store-operated Ca^{2+} entry; LTP, long-term potentiation; RIPH, remifentanyl-induced hyperalgesia.

Abbreviations

RIPH, remifentanil-induced postoperative hyperalgesia; SOCCs, store-operated calcium channels; STIM1, stromal interaction molecules 1; CaMKII α , Ca²⁺/calmodulin-dependent protein kinase II α ; PWTL, paw withdrawal thermal latency; PWMT, paw withdrawal mechanical threshold; ER, endoplasmic reticulum; SOCE, store-operated Ca²⁺ entry; LTP, long-term potentiation; CNS, central nervous system; PD, Parkinson's disease; AD, Alzheimer's disease; SNI, spared nerve injury; PBS, phosphate buffer saline; PFA, paraformaldehyde; SEM, standard error of measurement; ANOVA, analysis of variance; OIH, opioid-induced hyperalgesia; RIH, remifentanil-induced hyperalgesia.

Data Sharing Statement

The datasets used during the present study are available from the corresponding author upon reasonable request.

Author Contributions

Zhenhui Zhou: This author helped design the study, conduct the study, analyze the data, and write the manuscript; Meng Mao: This author helped conduct the study, analyze the data, and prepare the manuscript; Xuechun Cai: This author helped analyze the data and prepare the manuscript; Wei Zhu: This author helped design the study, prepare the manuscript; Jie Sun: This author helped design the study, analyze the data, prepare the manuscript, and obtain the research fund. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Funding

This work was supported by the National Natural Science Foundation of China (No.82071196), the Jiangsu Commission of Health (No. z201949) and the Basic Research Grant of Southeast University.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Yu EHY, Tran DHD, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? *Anaesthesia*. 2016;71(11):1347–1362. doi:10.1111/anae.13602

2. Comelon M, Raeder J, Stubhaug A, Nielsen CS, Draegni T, Lenz H. Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia. *Br J Anaesth*. 2016;116(4):524–530. doi:10.1093/bja/aev547
3. Zhang L, Shu R, Zhao Q, Li Y, Yu Y, Wang G. Preoperative butorphanol and flurbiprofen axetil therapy attenuates remifentanil-induced hyperalgesia after laparoscopic gynaecological surgery: a randomized double-blind controlled trial. *Br J Anaesth*. 2016;117(4):504–511. doi:10.1093/bja/aew248
4. Zhang L, Guo S, Zhao Q, et al. Spinal protein kinase m ζ regulates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking and dendritic spine plasticity via kalirin-7 in the pathogenesis of remifentanil-induced postincisional hyperalgesia in rats. *Anesthesiology*. 2018;129(1):173–186. doi:10.1097/ALN.0000000000002190
5. Gao Y, Zhou S, Pan Y, Gu L, He Y, Sun J. Wnt3a inhibitor attenuates remifentanil-induced hyperalgesia via downregulating spinal NMDA receptor in rats. *J Pain Res*. 2020;13:1049–1058. doi:10.2147/JPR.S250663
6. Munoz F, Hu H. The role of store-operated calcium channels in pain. *Adv Pharmacol*. 2016;75:139.
7. Desvignes L, Weidinger C, Shaw P, et al. STIM1 controls T cell-mediated immune regulation and inflammation in chronic infection. *J Clin Invest*. 2015;125(6):2347–2362. doi:10.1172/JCI80273
8. Wei F, Vadakkan KI, Toyoda H, et al. Calcium calmodulin-stimulated adenylyl cyclases contribute to activation of extracellular signal-regulated kinase in spinal dorsal horn neurons in adult rats and mice. *J Neurosci*. 2006;26(3):851–861. doi:10.1523/JNEUROSCI.3292-05.2006
9. Kuang X, Liu Y, Chang Y, et al. Inhibition of store-operated calcium entry by sub-lethal levels of proteasome inhibition is associated with STIM1/STIM2 degradation. *Cell Calcium*. 2016;59(4):172–180. doi:10.1016/j.ceca.2016.01.007
10. Ryazantseva M, Goncharova A, Skobeleva K, et al. Presenilin-1 delta E9 mutant induces STIM1-driven store-operated calcium channel hyperactivation in hippocampal neurons. *Mol Neurobiol*. 2018;55(6):4667–4680. doi:10.1007/s12035-017-0674-4
11. Qi Z, Wang Y, Zhou H, et al. The central analgesic mechanism of YM-58483 in attenuating neuropathic pain in rats. *Cell Mol Neurobiol*. 2016;36(7):1035–1043. doi:10.1007/s10571-015-0292-5
12. Gao X, Xia J, Munoz FM, et al. STIMs and Orai1 regulate cytokine production in spinal astrocytes. *J Neuroinflamm*. 2016;13:1–13. doi:10.1186/s12974-016-0594-7
13. Gao R, Gao X, Xia J, et al. Potent analgesic effects of a store-operated calcium channel inhibitor. *Pain*. 2013;154(10):2034–2044. doi:10.1016/j.pain.2013.06.017
14. Gao XH, Gao R, Tian YZ, et al. A store-operated calcium channel inhibitor attenuates collagen-induced arthritis. *Brit J Pharmacol*. 2015;172(12):2991–3002. doi:10.1111/bph.13104
15. Qi F, Liu T, Zhang X, et al. Ketamine reduces remifentanil-induced postoperative hyperalgesia mediated by CaMKII-NMDAR in the primary somatosensory cerebral cortex region in mice. *Neuropharmacology*. 2020;162:107783. doi:10.1016/j.neuropharm.2019.107783
16. Cui W, Wang S, Han R, Wang Q, Li J. CaMKII phosphorylation in primary somatosensory cortical neurons is involved in the inhibition of remifentanil-induced hyperalgesia by lidocaine in male Sprague-Dawley rats. *J Neurosurg Anesthesiol*. 2016;28(1):44–50. doi:10.1097/ANA.0000000000000177
17. Zhou Y, Liu D, Chen S, et al. Cellular and molecular mechanisms of calcium/calmodulin-dependent protein kinase II in chronic pain. *J Pharmacol Exp Ther*. 2017;363(2):176–183. doi:10.1124/jpet.117.243048
18. Herring BE, Nicoll RA. Long-term potentiation: from CaMKII to AMPA receptor trafficking. *Annu Rev Physiol*. 2016;78(1):351–365. doi:10.1146/annurev-physiol-021014-071753

19. Cai Q, Zeng M, Wu X, et al. CaMKIIalpha-driven, phosphatase-checked postsynaptic plasticity via phase separation. *Cell Res.* 2021;31(1):37–51. doi:10.1038/s41422-020-00439-9
20. Wang Q, Zhao X, Li S, Han S, Peng Z, Li J. Phosphorylated CaMKII levels increase in rat central nervous system after large-dose intravenous remifentanyl. *Med Sci Monit Basic Res.* 2013;19:118–125. doi:10.12659/MSMBR.883866
21. Ali ES, Rychkov GY, Barritt GJ. Metabolic disorders and cancer: hepatocyte store-operated Ca(2+) channels in nonalcoholic fatty liver disease. *Adv Exp Med Biol.* 2017;993:595–621.
22. Brennan TJ, Vandermeulen EP, Gebhart GF. Characterization of a rat model of incisional pain. *Pain.* 1996;64(3):493–501. doi:10.1016/0304-3959(95)01441-1
23. Mestre C, Pelissier T, Fialip J, Wilcox G, Eschaliere A. A method to perform direct transcutaneous intrathecal injection in rats. *J Pharmacol Toxicol Methods.* 1994;32(4):197–200. doi:10.1016/1056-8719(94)90087-6
24. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. *J Neurosci Meth.* 1994;53(1):55–63. doi:10.1016/0165-0270(94)90144-9
25. Sun J, Chen SR, Chen H, Pan HL. μ -Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid-induced hyperalgesia. *J Physiol.* 2019;597(6):1661–1675. doi:10.1113/JP277428
26. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. *Lancet Neurol.* 2014;13(9):924–935. doi:10.1016/S1474-4422(14)70102-4
27. Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. *CNS Drugs.* 2019;33(10):943–955. doi:10.1007/s40263-019-00660-0
28. Santonocito C, Noto A, Crimi C, Sanfilippo F. Remifentanyl-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. *Local Reg Anesth.* 2018;11:15–23. doi:10.2147/LRA.S143618
29. Martorano PP, Aloj F, Baietta S, et al. Sufentanyl-propofol vs remifentanyl-propofol during total intravenous anesthesia for neurosurgery. A multicentre study. *Minerva Anesthesiol.* 2008;74(6):233–243.
30. Roeckel L, Le Coz G, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. *Neuroscience.* 2016;338:160–182.
31. Shu RC, Zhang LL, Wang CY, et al. Spinal peroxynitrite contributes to remifentanyl-induced postoperative hyperalgesia via enhancement of divalent metal transporter 1 without iron-responsive element-mediated iron accumulation in rats. *Anesthesiology.* 2015;122(4):908–920. doi:10.1097/ALN.0000000000000562
32. Berna-Erro A, Braun A, Kraft R, et al. STIM2 regulates capacitive Ca²⁺ entry in neurons and plays a key role in hypoxic neuronal cell death. *Sci Signal.* 2009;2(93):a67. doi:10.1126/scisignal.2000522
33. Baba A, Yasui T, Fujisawa S, et al. Activity-evoked capacitative Ca²⁺ entry: implications in synaptic plasticity. *J Neurosci.* 2003;23(21):7737–7741. doi:10.1523/JNEUROSCI.23-21-07737.2003
34. Stathopoulos PB, Schindl R, Fahrner M, et al. STIM1/Orai1 coiled-coil interplay in the regulation of store-operated calcium entry. *Nat Commun.* 2013;4:2963. doi:10.1038/ncomms3963
35. Gemes G, Bangaru ML, Wu HE, et al. Store-operated Ca²⁺ entry in sensory neurons: functional role and the effect of painful nerve injury. *J Neurosci.* 2011;31(10):3536–3549. doi:10.1523/JNEUROSCI.15053-10.2011
36. Sztteyn K, Gomez R, Berg KA, Jeske NA. Divergence in endothelin-1- and bradykinin-activated store-operated calcium entry in afferent sensory neurons. *Asn Neuro.* 2015;7:2. doi:10.1177/1759091415578714
37. Chen Y, Yang C, Wang ZJ. Ca²⁺/calmodulin-dependent protein kinase II is required for the initiation and maintenance of opioid-induced hyperalgesia. *J Neurosci.* 2010;30(1):38–46. doi:10.1523/JNEUROSCI.4346-09.2010
38. Yuan Y, Sun Z, Chen Y, et al. Prevention of remifentanyl induced postoperative hyperalgesia by dexmedetomidine via regulating the trafficking and function of spinal NMDA receptors as well as PKC and CaMKII level in vivo and in vitro. *PLoS One.* 2017;12(2):e171348.
39. Zhou J, Qi F, Hu Z, et al. Dezocine attenuates the remifentanyl-induced postoperative hyperalgesia by inhibition of phosphorylation of CaMKII α . *Eur J Pharmacol.* 2020;869:172882. doi:10.1016/j.ejphar.2019.172882
40. Voelkers M, Salz M, Herzog N, et al. Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. *J Mol Cell Cardiol.* 2010;48(6):1329–1334. doi:10.1016/j.yjmcc.2010.01.020